Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $245.00 at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective lifted by JPMorgan Chase & Co. from $200.00 to $245.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 42.39% from the company’s current price.

Several other analysts have also commented on ASND. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Royal Bank of Canada initiated coverage on Ascendis Pharma A/S in a research report on Wednesday, April 16th. They set an “outperform” rating and a $205.00 price target on the stock. Cantor Fitzgerald upped their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. Wedbush boosted their target price on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an “outperform” rating in a report on Friday. Finally, The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $211.40.

Ascendis Pharma A/S Stock Up 2.7 %

Shares of ASND stock opened at $172.06 on Friday. The firm has a market capitalization of $10.49 billion, a price-to-earnings ratio of -24.23 and a beta of 0.41. The stock has a fifty day moving average of $155.31 and a 200 day moving average of $140.33. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million for the quarter, compared to analysts’ expectations of $98.56 million. Equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently made changes to their positions in ASND. RA Capital Management L.P. lifted its position in Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock valued at $1,392,221,000 after acquiring an additional 402,316 shares in the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 2.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company’s stock worth $702,538,000 after purchasing an additional 114,167 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Ascendis Pharma A/S by 0.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company’s stock worth $612,689,000 after purchasing an additional 39,309 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Ascendis Pharma A/S by 4.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company’s stock valued at $602,910,000 after purchasing an additional 193,688 shares in the last quarter. Finally, Capital International Investors boosted its position in shares of Ascendis Pharma A/S by 35.7% during the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock valued at $394,183,000 after buying an additional 753,859 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.